|
1
|
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.
|
Clin Infect Dis
|
2013
|
1.53
|
|
2
|
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.
|
PLoS Med
|
2006
|
1.40
|
|
3
|
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.
|
Clin Infect Dis
|
2013
|
1.23
|
|
4
|
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
|
AIDS
|
2015
|
1.05
|
|
5
|
Genetic analysis implicates resistin in HIV lipodystrophy.
|
AIDS
|
2008
|
0.96
|
|
6
|
Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
|
AIDS
|
2010
|
0.96
|
|
7
|
Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.
|
J Infect Dis
|
2013
|
0.93
|
|
8
|
Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2005
|
0.86
|
|
9
|
Metabolic effects of nandrolone decanoate and resistance training in men with HIV.
|
Am J Physiol Endocrinol Metab
|
2002
|
0.85
|
|
10
|
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
|
J Infect Dis
|
2003
|
0.84
|
|
11
|
Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.
|
AIDS
|
2016
|
0.82
|
|
12
|
Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.
|
J Acquir Immune Defic Syndr
|
2016
|
0.81
|
|
13
|
Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.
|
AIDS Res Hum Retroviruses
|
2013
|
0.77
|
|
14
|
Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.
|
AIDS
|
2016
|
0.76
|
|
15
|
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|